Health Condition 1: K746- Other and unspecified cirrhosis ofliver
Conditions
Interventions
Intervention1: Albumin: Dose: Those with serum albumin levels between 3-3.5 gm/dL will receive 100 mL of 20% human albumin solution.Those with 2.5-3 gm/dL will receive 200 mL of 20% human albumin solu
Sponsors
Institute of Liver and Biliary Sciences
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years and 2. Decompensated cirrhosis of any cause 3. S. Albumin 4. Written informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients of ACLF 2. Patients admitted with proven indications for albumin (SBP, HRS, LVP) 3. Advanced HCC 4. Presence of hypotension 5. PF ratios 6. IVC Collapsibility Index 7. Albumin infusion within the past 3 weeks 8. Post liver transplant patients 9. AKI or CKD 10. Known or suspected cardiac dysfunction 11. Acute GI Bleed 12. Severe Anemia 13. Pregnant women 14. PLHA 15. Severe psychiatric disorders 16. Lack of informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To study the effect of albumin on ROTEM based coagulation parameters within the first week in decompensated cirrhotic patientsTimepoint: 1 week | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse effects of HASTimepoint: 7 days;Alterations in the albuminomeTimepoint: 7 days;Changes in endothelial dysfunctionTimepoint: 7 days;Changes in inflammatory parametersTimepoint: 7 days;Duration of hospital stayTimepoint: 28 days;Effect on cardio-pulmonary and renal functionTimepoint: 7 days;Mortality at 28 daysTimepoint: 28 days | — |
Countries
India
Contacts
Public ContactDr Manoj Kumar Sharma
Institute of Liver and Biliary Sciences
Outcome results
None listed